MARKET

ELEV

ELEV

Elevation Oncolo
NASDAQ
0.3490
-0.0113
-3.14%
Closed 19:46 05/13 EDT
OPEN
0.3582
PREV CLOSE
0.3603
HIGH
0.3700
LOW
0.3421
VOLUME
405.55K
TURNOVER
--
52 WEEK HIGH
4.330
52 WEEK LOW
0.2210
MARKET CAP
20.67M
P/E (TTM)
-0.4493
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ELEV last week (0505-0509)?
Weekly Report · 2d ago
Insmed's Q1 Loss Wider Than Expected, Sales Match Estimates
NASDAQ · 4d ago
Iovance's Q1 Earnings & Sales Miss, Stock Slides 39% on '25 View Cut
NASDAQ · 4d ago
Perrigo Q1 Earnings Beat Estimates, Revenues Decline Y/Y
NASDAQ · 6d ago
JAZZ Misses Q1 Earnings & Sales Estimates, Cuts '25 EPS Outlook
Barchart · 6d ago
Weekly Report: what happened at ELEV last week (0428-0502)?
Weekly Report · 05/05 09:13
William Blair Reaffirms Their Buy Rating on Elevation Oncology (ELEV)
TipRanks · 04/28 17:15
Weekly Report: what happened at ELEV last week (0421-0425)?
Weekly Report · 04/28 09:15
More
About ELEV
More
Elevation Oncology, Inc. is an oncology company. The Company is focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. Its lead product candidate, EO-3021 is an antibody-drug conjugate (ADC) designed to target Claudin 18.2, which can selectively deliver a cytotoxic payload directly to cancer cells expressing Claudin 18.2. EO-3021 consists of a fully human immunoglobulin G1 (IgG1) mAb that targets Claudin 18.2 and is site-specifically conjugated to the monomethyl auristatin E (MMAE) payload via a cleavable linker with a drug-to-antibody ratio (DAR) of 2. EO-3021 is designed to bind to Claudin 18.2 on the cell surface and is internalized, upon which the linker is cleaved in the lysosome to release the MMAE payload, a potent anti-mitotic agent. Its second program is an ADC designed to target HER3, which is overexpressed across solid tumors.
Recently
Symbol
Price
%Change

Webull offers Elevation Oncology Inc stock information, including NASDAQ: ELEV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ELEV stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ELEV stock methods without spending real money on the virtual paper trading platform.